Skip to main content

20212222 EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields,150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

NCT04892472

EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields,150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Associated Conditions

Lung Cancer

Principal Investigator

Sponsor

Novocure GmbH

This study involves collecting data on the
clinical results of an experimental device, the NovoTTF-200T, concomitant with a
standard immunotherapy agent, pembrolizumab, for a first line treatment of your lung
cancer. Tumor Treating Fields (TTFields) are a type of low intensity electric fields delivered
using a small medical device. The fields are directed to the anatomical region where
your cancer is, and are intended to kill dividing cancer cells.
Pembrolizumab is an immunotherapy and it works with your immune system to help
fight cancer.
Pembrolizumab may be used alone as your first treatment when your lung cancer has
not spread outside your chest (stage III) and you cannot have surgery or
chemotherapy with radiation, or your lung cancer has spread to other areas of your
body (stage IV), and your tumor tests make it suitable for this treatment.
Once your doctor has determined that you meet all of the requirements for
participation in the study, you will be enrolled within 28 days of signing the Patient
Informed Consent Form. You will receive treatment with both Tumor Treating Fields
and pembrolizumab.

This study is currently enrolling.